Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naproxen + chitosan refers to a **nanoparticle-based drug delivery system** in which **naproxen**, a non-steroidal anti-inflammatory drug (NSAID), is encapsulated within **chitosan** nanoparticles. This formulation aims to enhance the delivery, controlled release, and potentially the efficacy of naproxen. Chitosan is a natural, biodegradable polymer that enables the formation of nanoparticles via ionic gelation, typically with crosslinkers such as tripolyphosphate. The nanoparticles can improve drug stability, modulate release kinetics, and may exhibit antibacterial and antioxidant properties in addition to the anti-inflammatory action of naproxen. Research demonstrates activity against both Gram-positive and Gram-negative bacteria, as well as antifungal and superoxide dismutase-like antioxidant activity[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naproxen + chitosan.